MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve chemotherapy efficacy.